The RALES and EPHESUS trials have provided data demonstrating survival benefits with spironolactone and eplerenone in chronic and postinfarction heart failure, leading to more frequent and sometimes unbridled use of these drugs. Here Kalidindi et al. describe the likely mechanisms of action of aldosterone-receptor antagonists, discuss the evidence supporting their use, and provide practical advice.
- Srinivasa R Kalidindi
- WH Wilson Tang
- Gary S Francis
